These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18180061)

  • 41. Urocortins as biomarkers in cardiovascular disease.
    Vasconcelos I; Adão R; Rademaker MT; Leite-Moreira AF; Fontes-Sousa AP; Brás-Silva C
    Clin Sci (Lond); 2022 Jan; 136(1):1-14. PubMed ID: 34939089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of urocortin I and its related peptide urocortin II by inflammatory and oxidative stresses in HL-1 cardiomyocytes.
    Ikeda K; Tojo K; Inada Y; Takada Y; Sakamoto M; Lam M; Claycomb WC; Tajima N
    J Mol Endocrinol; 2009 Jun; 42(6):479-89. PubMed ID: 19318426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of cardiovascular magnetic resonance imaging in heart failure.
    Karamitsos TD; Francis JM; Myerson S; Selvanayagam JB; Neubauer S
    J Am Coll Cardiol; 2009 Oct; 54(15):1407-24. PubMed ID: 19796734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exercise training in the management of cardiac failure and ischaemic heart disease.
    Joshi SB
    Heart Lung Circ; 2007; 16 Suppl 3():S83-7. PubMed ID: 17606403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [N-terminal fragment of the brain natriuretic peptide and proinflammatory cytokines in patients with ischemic heart disease].
    Shalaev SV; Volkova SIu
    Ter Arkh; 2009; 81(5):30-6. PubMed ID: 19537583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients.
    Ranchord AM; Harding SA; Pidgeon G
    Intern Med J; 2008 May; 38(5):361-4. PubMed ID: 18402563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Placental urocortins and CRF in late gestation.
    Pepels PP; Spaanderman ME; Bulten J; Smits PB; Hermus AR; Lotgering FK; Sweep CG
    Placenta; 2009 Jun; 30(6):483-90. PubMed ID: 19359038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury.
    Moos MP; Funk CD
    Trends Cardiovasc Med; 2008 Oct; 18(7):268-73. PubMed ID: 19232956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ultrafiltration for decompensated heart failure: renal implications.
    Kazory A; Ross EA
    Heart; 2009 Jul; 95(13):1047-51. PubMed ID: 19261603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions?
    Talha S; Di Marco P; Doutreleau S; Rouyer O; Piquard F; Geny B
    Clin Transplant; 2008; 22(5):542-8. PubMed ID: 18394002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The myocardial JAK/STAT pathway: from protection to failure.
    Boengler K; Hilfiker-Kleiner D; Drexler H; Heusch G; Schulz R
    Pharmacol Ther; 2008 Nov; 120(2):172-85. PubMed ID: 18786563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urocortin: advancing the neurohumoral hypothesis of heart failure.
    Burnett JC
    Circulation; 2005 Dec; 112(23):3544-6. PubMed ID: 16330694
    [No Abstract]   [Full Text] [Related]  

  • 54. The Urocortins: mechanisms of cardioprotection and therapeutic potential.
    Lawrence KM; Latchman DS
    Mini Rev Med Chem; 2006 Oct; 6(10):1119-26. PubMed ID: 17073712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploring new drugs for heart failure: the case of urocortin.
    Tang WH; Francis GS
    Eur Heart J; 2007 Nov; 28(21):2561-2. PubMed ID: 17905792
    [No Abstract]   [Full Text] [Related]  

  • 56. [The role of endorphins in the etiopathogenesis of circulatory diseases].
    Salomon P
    Pol Merkur Lekarski; 1999 Aug; 7(38):37-9. PubMed ID: 10522412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta-analysis.
    Kovács DK; Farkas N; Soós A; Hegyi P; Kelava L; Eitmann S; Schekk A; Molnár Z; Erőss B; Balaskó M
    Clin Transl Sci; 2021 Nov; 14(6):2461-2473. PubMed ID: 34378854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel neurohormonal insights with therapeutic potential in chronic heart failure.
    Dalzell JR; Jackson CE
    Future Cardiol; 2010 May; 6(3):361-72. PubMed ID: 20462342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into the mechanisms underlying vascular and cardiac effects of urocortin.
    Díaz I; Smani T
    Curr Vasc Pharmacol; 2013 Jul; 11(4):457-64. PubMed ID: 23905640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Vegetarian diet in treating elderly patients with ischemic heart disease (clinico-hemodynamic, biochemical, and hemorheological effects)].
    Ivanov AN; Medkova IL; Mosiagina LI
    Vopr Pitan; 2002; 71(3):11-4. PubMed ID: 12227010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.